Literature DB >> 8964830

Highly specific cytochrome P450-like enzymes for all-trans-retinoic acid in T47D human breast cancer cells.

I S Han1, J H Choi.   

Abstract

When human breast cancer T47D cells were treated with all-trans-retinoic acid (RA), the RA 4- and 18-hydroxylase activities were induced in microsomes in a time-dependent manner, indicating that these cells readily metabolized RA into more polar compounds, such as all-trans-4-hydroxy-RA and all-trans-18-hydroxy-RA. In contrast, T47D cells treated for 12 h with xenobiotics, such as phenobarbital, beta-naphthoflavone, 3-methylcholanthrene, and dimethylsulfoxide, showed lower levels of catalytic activities for 4- and 18-hydroxylases. The induction of 4- and 18-hydroxylase activities appears to be regulated at the level of transcriptional control (basal level). Competitive assays demonstrated that inhibitors and substrates for 1A, 2A, 3A, 2B, and 2C cytochrome P450 (P450 subfamilies), all-trans-retinol, and all-trans-retinal showed no inhibition of RA metabolism, but other retinoic acid derivatives competed highly with RA. The RA-inducible 4- and 18-hydroxylases showed high specificity for RA and high levels of catalytic activities, with Km and maximum velocity values for 4-hydroxylase equal to 99 nmol/L and 0.26 pmol/min.mg protein, respectively, and those for 18-hydroxylase equal to 65 nmol/L and 0.18 pmol/min.mg protein. Cell-free metabolism of RA required microsomes from RA-treated cells and NADPH, and was inhibited by liarozole, an inhibitor of P450. These data suggest that RA-inducible 4- and 18-hydroxylases may be novel P450 isozymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8964830     DOI: 10.1210/jcem.81.6.8964830

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.

Authors:  Puranik Purushottamachar; Jyoti B Patel; Lalji K Gediya; Omoshile O Clement; Vincent C O Njar
Journal:  Eur J Med Chem       Date:  2011-11-17       Impact factor: 6.514

Review 2.  Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Authors:  Cara H Nelson; Brian R Buttrick; Nina Isoherranen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

3.  Induction of the oxidative catabolism of retinoid acid in MCF-7 cells.

Authors:  M D Krekels; A Verhoeven; J van Dun; W Cools; C Van Hove; L Dillen; M C Coene; W Wouters
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  All-trans-retinoic acid metabolites significantly inhibit the proliferation of MCF-7 human breast cancer cells in vitro.

Authors:  J Van heusden; W Wouters; F C Ramaekers; M D Krekels; L Dillen; M Borgers; G Smets
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity.

Authors:  J Van Heusden; R Van Ginckel; H Bruwiere; P Moelans; B Janssen; W Floren; B J van der Leede; J van Dun; G Sanz; M Venet; L Dillen; C Van Hove; G Willemsens; M Janicot; W Wouters
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

6.  Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.

Authors:  C K Huynh; A M H Brodie; V C O Njar
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.